CG Oncology, Cash Flow From Operations vs. Revenue
| CGON Stock | 34.75 0.65 1.91% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 1.06 | 0.9215 |
|
|
For CG Oncology, profitability analysis, we use financial ratios and fundamental drivers that measure the ability of CG Oncology, to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well CG Oncology, Common utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between CG Oncology,'s most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of CG Oncology, Common over time as well as its relative position and ranking within its peers.
CGON |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CG Oncology,. If investors know CGON will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CG Oncology, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (15.87) | Revenue Per Share 0.015 | Quarterly Revenue Growth 3.778 | Return On Assets (0.16) | Return On Equity (0.20) |
The market value of CG Oncology, Common is measured differently than its book value, which is the value of CGON that is recorded on the company's balance sheet. Investors also form their own opinion of CG Oncology,'s value that differs from its market value or its book value, called intrinsic value, which is CG Oncology,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CG Oncology,'s market value can be influenced by many factors that don't directly affect CG Oncology,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CG Oncology,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if CG Oncology, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CG Oncology,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
CG Oncology, Common Revenue vs. Cash Flow From Operations Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining CG Oncology,'s current stock value. Our valuation model uses many indicators to compare CG Oncology, value to that of its competitors to determine the firm's financial worth. CG Oncology, Common is number one stock in cash flow from operations category among its peers. It also is the top company in revenue category among its peers . At this time, CG Oncology,'s Total Revenue is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the CG Oncology,'s earnings, one of the primary drivers of an investment's value.CGON Revenue vs. Cash Flow From Operations
Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
CG Oncology, |
| = | (45.68 M) |
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
CG Oncology, |
| = | 204 K |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
CGON Revenue vs Competition
CG Oncology, Common is the top company in revenue category among its peers. Market size based on revenue of Health Care industry is currently estimated at about 47.05 Billion. CG Oncology, adds roughly 204,000 in revenue claiming only tiny portion of equities under Health Care industry.
CG Oncology, Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in CG Oncology,, profitability is also one of the essential criteria for including it into their portfolios because, without profit, CG Oncology, will eventually generate negative long term returns. The profitability progress is the general direction of CG Oncology,'s change in net profit over the period of time. It can combine multiple indicators of CG Oncology,, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -2.7 K | -2.8 K | |
| Net Interest Income | 6.9 M | 7.2 M | |
| Operating Income | -55.4 M | -52.7 M | |
| Net Loss | -48.6 M | -51 M | |
| Income Before Tax | -48.6 M | -51 M | |
| Total Other Income Expense Net | 6.8 M | 7.2 M | |
| Net Loss | -48.6 M | -51 M | |
| Net Loss | (11.22) | (10.66) | |
| Income Quality | 0.94 | 1.05 |
CGON Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on CG Oncology,. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of CG Oncology, position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the CG Oncology,'s important profitability drivers and their relationship over time.
Use CG Oncology, in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CG Oncology, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CG Oncology, will appreciate offsetting losses from the drop in the long position's value.CG Oncology, Pair Trading
CG Oncology, Common Pair Trading Analysis
The ability to find closely correlated positions to CG Oncology, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CG Oncology, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CG Oncology, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CG Oncology, Common to buy it.
The correlation of CG Oncology, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CG Oncology, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CG Oncology, Common moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CG Oncology, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your CG Oncology, position
In addition to having CG Oncology, in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Long/short ETFs Thematic Idea Now
Long/short ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Long/short ETFs theme has 24 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Long/short ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
To fully project CG Oncology,'s future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of CG Oncology, Common at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include CG Oncology,'s income statement, its balance sheet, and the statement of cash flows.